NCT03691519 (LO-MAPT) is a Phase 3 clinical trial of Omega-3 treatment in Alzheimer Disease, sponsored by University Hospital, Toulouse.

Who is sponsoring NCT03691519?

NCT03691519 is sponsored by University Hospital, Toulouse.

What drugs are being tested in NCT03691519?

Interventions in NCT03691519: Omega-3 treatment, Placebo.

What condition does NCT03691519 study?

NCT03691519 studies Alzheimer Disease.

Is NCT03691519 still recruiting?

NCT03691519 is currently completed. Last updated 24 August 2023.

Last reviewed 2023-08-24 · How we verify

NCT03691519: LO-MAPT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prevention of Cognitive Decline in Older Adults With Low Dha/Epa Index in Red Blood Cells

Completed Phase 3 Last updated 24 August 2023

What this trial tests

Phase 3 trial testing Omega-3 treatment in Alzheimer Disease in 774 participants. Completed in 31 March 2020.

Timeline

17 April 2018

Primary endpoint
31 March 2020

31 March 2020

Quick facts

Lead sponsor	University Hospital, Toulouse
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	prevention
Enrollment	774
Start date	17 April 2018
Primary completion	31 March 2020
Estimated completion	31 March 2020
Sites	1 location across France

Drugs / interventions tested

Omega-3 treatment — full drug profile →
Placebo

Conditions studied

Alzheimer Disease — all drugs for Alzheimer Disease →

Sponsor

University Hospital, Toulouse

Who can join

70 and older, any sex, with Alzheimer Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

LO MAPT is an 18-month, phase III, multicenter, randomized, placebo-controlled, 2 parallel groups trial, followed by a 18-month open-label extension phase, to evaluate the efficacy of omega-3 supplementation on cognitive decline in older adults with low DHA/EPA status and subjective memory complaints or family history of Alzheimer disease.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Alzheimer's disease drug development pipeline: 2022.
Cummings J, Lee G, Nahed P, Kambar MEZN, et al · · 2022 · cited 369× · PMID 35516416 · DOI 10.1002/trc2.12295
Alzheimer's disease drug development pipeline: 2023.
Cummings J, Zhou Y, Lee G, Zhong K, et al · · 2023 · cited 326× · PMID 37251912 · DOI 10.1002/trc2.12385
Alzheimer's disease drug development pipeline: 2021.
Cummings J, Lee G, Zhong K, Fonseca J, et al · · 2021 · cited 312× · PMID 34095440 · DOI 10.1002/trc2.12179
Pathological mechanisms and therapeutic strategies for Alzheimer's disease.
Ju Y, Tam KY. · · 2022 · cited 260× · PMID 34380884 · DOI 10.4103/1673-5374.320970
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.
Abdelhamid AS, Brown TJ, Brainard JS, Biswas P, et al · · 2020 · cited 203× · PMID 32114706 · DOI 10.1002/14651858.cd003177.pub5
Role of Oxidative Damage in Alzheimer's Disease and Neurodegeneration: From Pathogenic Mechanisms to Biomarker Discovery.
Buccellato FR, D'Anca M, Fenoglio C, Scarpini E, et al · · 2021 · cited 95× · PMID 34572985 · DOI 10.3390/antiox10091353
The Impact of Nutrients on Mental Health and Well-Being: Insights From the Literature.
Muscaritoli M. · · 2021 · cited 87× · PMID 33763446 · DOI 10.3389/fnut.2021.656290
Alzheimer's Disease: Novel Targets and Investigational Drugs for Disease Modification.
Cummings JL, Osse AML, Kinney JW. · · 2023 · cited 75× · PMID 37728864 · DOI 10.1007/s40265-023-01938-w

Verify or expand the search:

Other recruiting trials for Alzheimer Disease

Currently open trials in the same condition.

NCT07290387 — Tele-Savvy for Latino Caregivers · NA · recruiting
NCT07178210 — Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease · NA · recruiting
NCT07294885 — Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease · NA · recruiting
NCT06937229 — A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) · Phase 3 · recruiting
NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms · NA · recruiting

Other University Hospital, Toulouse trials

Trials by the same sponsor.

NCT07497750 — Impact of Artificial Intelligence Algorithm-driven Versus Standard Lifestyle Intervention in Non-Alcoholic Fatty Liver D · NA · not yet recruiting
NCT07507240 — The Benefits of a Care Pathway Combining Remote Monitoring and Support From a Nurse After a Change in Anti-epileptic Tre · NA · not yet recruiting
NCT07524088 — Contamination of Young Children Hair During Acute Cannabis Intoxication · NA · not yet recruiting
NCT07470580 — Radiofrequency Ablation Versus Adrenalectomy for Adenoma in Patients With Primary Aldosteronism and Hypertension · NA · not yet recruiting
NCT07423988 — Evaluation of Changes in Sleep Efficiency Among PIC DU MIDI Staff Between Nights Spent at Home and Nights Spent in the W · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03691519 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Toulouse
Last refreshed: 24 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03691519.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing